Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Virology ; 402(2): 228-37, 2010 Jul 05.
Article in English | MEDLINE | ID: mdl-20399480

ABSTRACT

We measured the effects of non-nucleoside reverse transcriptase (RT) inhibitor-resistant mutations K101E+G190S, on replication fitness and EFV-resistance of HIV(NL4-3). K101E+G190S reduced fitness in the absence of EFV and increased EFV resistance, compared to either single mutant. Unexpectedly, K101E+G190S also replicated more efficiently in the presence of EFV than in its absence. Addition of the nucleoside resistance mutations L74V or M41L+T215Y to K101E+G190S improved fitness and abolished EFV-dependent stimulation of replication. D10, a clinical RT backbone containing M41L+T215Y and K101E+G190S, also demonstrated EFV-dependent stimulation that was dependent on the presence of K101E. These studies demonstrate that non-nucleoside reverse transcriptase inhibitors can stimulate replication of NNRTI-resistant HIV-1 and that nucleoside-resistant mutants can abolish this stimulation. The ability of EFV to stimulate NNRTI-resistant mutants may contribute to the selection of HIV-1 mutants in vivo. These studies have important implications regarding the treatment of HIV-1 with combination nucleoside and non-nucleoside therapies.


Subject(s)
Anti-HIV Agents/pharmacology , Benzoxazines/pharmacology , HIV Reverse Transcriptase/genetics , HIV-1/growth & development , Mutation, Missense , Virus Replication/drug effects , Alkynes , Cells, Cultured , Cyclopropanes , Drug Resistance, Viral , HIV Infections/virology , HIV-1/drug effects , HIV-1/genetics , Humans , Mutagenesis, Site-Directed , RNA, Viral/genetics , Sequence Analysis, DNA
2.
Virology ; 348(2): 462-74, 2006 May 10.
Article in English | MEDLINE | ID: mdl-16504235

ABSTRACT

We evaluated the replication efficiency of the HIV reverse transcriptase (RT) mutants K103N, G190A, and G190S, which confer resistance to the non-nucleoside RT inhibitor efavirenz, using growth competition assays in cell culture. In the absence of efavirenz, the fitness hierarchy was G190S < G190A < K103N < wild-type. The fitness reduction of G190S relative to K103N was less evident at high efavirenz concentrations, although K103N still replicated more efficiently. Efficiency of RNase H cleavage and RNA-dependent DNA synthesis from tRNA(Lys, 3) correlated with relative fitness, in biochemical studies of mutant RTs. Presteady state and steady state polymerization assays using DNA primers detected no abnormalities. This work is consistent with previous studies demonstrating that initiation of viral DNA synthesis is reduced in mutants with slowed RNase H cleavage, and suggests that both abnormalities contribute to the replication defect of these mutants. It also suggests that high concentrations of efavirenz are unlikely to favor the selection of G190S clinically.


Subject(s)
HIV Reverse Transcriptase/genetics , HIV-1/enzymology , HIV-1/genetics , Amino Acid Substitution , Base Sequence , Cell Line , DNA, Viral/biosynthesis , DNA, Viral/genetics , Drug Resistance, Viral/genetics , Genes, Viral , HIV-1/drug effects , HIV-1/physiology , Humans , Kinetics , Mutagenesis, Site-Directed , Point Mutation , RNA, Transfer, Lys/genetics , RNA, Transfer, Lys/metabolism , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H/metabolism , Virus Replication/genetics
3.
Ann Intern Med ; 135(11): 954-64, 2001 Dec 04.
Article in English | MEDLINE | ID: mdl-11730396

ABSTRACT

BACKGROUND: A substantial proportion of patients with HIV infection will not respond to antiretroviral therapy. Early predictors of response to treatment are needed to identify patients who are at risk for treatment failure. OBJECTIVE: To determine predictors of virologic and clinical response to indinavir, zidovudine, and lamivudine therapy. DESIGN: Observational analysis of one treatment group in a phase III trial. SETTING: 40 AIDS Clinical Trials units. PATIENTS: 489 patients receiving indinavir, zidovudine, and lamivudine who had 1) a CD4 count of 0.200 x 10(9) cells/L or less after 8 or more weeks of study therapy and 2) plasma HIV-1 RNA measurements obtained at baseline and week 8. MEASUREMENTS: HIV-1 RNA level and CD4 cell count at weeks 0, 4, 8, 24, and 40. Clinical progression was defined as a new AIDS-defining illness or death. RESULTS: Patients' levels of HIV-1 RNA at the 8th study week of therapy predicted whether patients would achieve virologic suppression to below 500 (or 50) copies/mL at study week 24. An HIV-1 RNA level less than 500 copies/mL at week 24 was achieved in 71% of patients whose level at week 8 had been less than 500 copies/mL, 53% of those with a level of 500 copies/mL or more and at least 2-log(10) copies/mL reduction since baseline, 29% of those with a level of 500 copies/mL or more with a 1- to 1.99-log(10) copies/mL reduction, and 9% of those with a level of 500 copies/mL or greater and less than 1-log(10) copies/mL reduction since baseline (P < 0.001). HIV-1 RNA level at week 8 also predicted clinical progression. HIV-1 disease progressed in 2.2% of the patients with a week-8 HIV-1 RNA level less than 500 copies/mL, 2.3% of patients with 500 copies/mL or greater and at least 2-log(10) copies/mL reduction since baseline, 4.9% of patients with 500 copies/mL or greater and 1- to 1.99-log(10) copies/mL reduction since baseline, and 10.6% of patients with 500 copies/mL or greater and less than 1-log(10) copies/mL decrease since baseline (P = 0.009). After adjustment for HIV-1 RNA level, patients with a higher week-8 CD4 cell count were more likely to have a week-24 HIV-1 RNA level less than 500 copies/mL (relative risk for patients with a week-8 CD4 count >/= 0.10 x 10(9) cells/L, 1.47 [95% CI, 1.00 to 2.16] compared with <0.050 x 10(9) cells/L; relative risk for patients with a week-8 CD4 count of 0.05 to 0.099 x 10(9) cells/L, 0.98 [CI, 0.61 to 1.57] compared with <0.050 x 10(9) cells/L). After adjustment for HIV-1 RNA level, patients with a week-8 CD4 count of 0.05 x 10(9) cells/L or greater (compared with <0.05 x 10(9) cells/L) had a decreased hazard for clinical progression (hazard ratio, 0.25 [CI, 0.09 to 0.67]). CONCLUSIONS: The HIV-1 RNA level and CD4 cell count achieved at 8 weeks of treatment are important predictors of subsequent virologic and clinical outcomes.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , HIV-1 , Indinavir/therapeutic use , Lamivudine/therapeutic use , Zidovudine/therapeutic use , Adult , CD4 Lymphocyte Count , Clinical Protocols , Disease Progression , Drug Therapy, Combination , Female , HIV-1/genetics , Humans , Logistic Models , Male , Middle Aged , RNA, Viral/blood , Viral Load
4.
J Virol ; 75(20): 9671-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11559799

ABSTRACT

Cellular tRNA(Lys)(3) serves as the primer for reverse transcription of human immunodeficiency virus type 1 (HIV-1). tRNA(Lys)(3) interacts directly with HIV-1 reverse transcriptase (RT), is packaged into viral particles, and anneals to the primer-binding site (PBS) of the HIV-1 genome in order to initiate reverse transcription. Residue A58 of tRNA(Lys)(3), which lies outside the PBS-complementary region, is posttranscriptionally methylated to form 1-methyladenosine 58 (M(1)A58). This methylation is thought to serve as a pause signal for plus-strand strong-stop DNA synthesis during reverse transcription. However, formal proof that the methylation is necessary for the pausing of RT has not been obtained in vivo. In the present study, we investigated the role of tRNA(Lys)(3) residue A58 in the replication cycle of HIV-1 in living cells. We have developed a mutant tRNA(Lys)(3) derivative, tRNA(Lys)(3)A58U, in which A58 was replaced by U. This mutant tRNA was expressed in CEM cells. We demonstrate that the presence of M(1)A58 is necessary for the appropriate termination of plus-strand strong-stop DNA synthesis and that the absence of M(1)A58 allows RT to read the tRNA sequences beyond residue 58. In addition, we show that replacement of M(1)A58 with U inhibits the replication of HIV-1 in vivo. These results highlight the importance of tRNA primer residue A58 in the reverse transcription process. Inhibition of reverse transcription with mutant tRNA primers constitutes a novel approach for therapeutic intervention against HIV-1.


Subject(s)
Adenosine/analogs & derivatives , HIV-1/genetics , RNA, Transfer, Amino Acyl/genetics , Adenosine/metabolism , Base Sequence , Cell Line , DNA, Viral/biosynthesis , HIV-1/metabolism , Humans , Methylation , Mutagenesis, Site-Directed , RNA, Transfer, Amino Acyl/metabolism , T-Lymphocytes/virology , Transcription, Genetic , Transfection , Virus Replication
5.
Virology ; 285(2): 193-203, 2001 Jul 05.
Article in English | MEDLINE | ID: mdl-11437654

ABSTRACT

We have shown that the HIV-1 laboratory strain NL4-3 that contains P236L [a reverse transcriptase mutation conferring resistance to the nonnucleoside reverse transcriptase inhibitor (NRTI) delavirdine] replicates more slowly than wild-type NL4-3. Other NNRTI-resistance mutations, such as K103N and Y181C, do not reduce the replication capacity of NL4-3 as much as P236L and develop more frequently in HIV-1 isolates from patients failing delavirdine. However, a minority of patients on delavirdine therapy still have isolates with P236L. We postulated that reverse transcriptase (RT) sequences from these patient isolates contain other mutations that compensate for the adverse effect of P236L. To test this hypothesis, we created 15 chimeric NL4-3 isolates that contained delavirdine-resistant RT sequences derived from eight patient isolates and characterized their replication kinetics. Nine of 10 patient-derived clones containing P236L replicated as slowly as NL4-3 with P236L. In contrast, three of five clones that did not have P236L (but had either K103N or Y181C) replicated significantly better than NL4-3 with P236L. Thus, the majority of patients who acquire P236L during delavirdine therapy do not have RT mutations that compensate for the replication defect conferred by P236L. We hypothesize that HIV-1 isolates with P236L may have a compensatory mutation outside RT. Alternatively, variants of HIV-1 with reduced replication fitness may be selected during antiretroviral therapy, suggesting that stochastic events rather than viral replication fitness may determine which drug-resistant mutants emerge early during antiretroviral failure. In some isolates, it appears that the background RT sequence can contribute significantly to the replication fitness of drug-resistant HIV-1 variants.


Subject(s)
Anti-HIV Agents/pharmacology , Delavirdine/pharmacology , HIV Infections/virology , HIV Reverse Transcriptase/genetics , HIV-1/enzymology , Reverse Transcriptase Inhibitors/pharmacology , Virus Replication , Anti-HIV Agents/therapeutic use , Cell Line , Delavirdine/therapeutic use , Drug Resistance, Microbial , HIV-1/drug effects , HIV-1/genetics , HIV-1/physiology , Humans , Reverse Transcriptase Inhibitors/therapeutic use , Virus Replication/genetics
6.
Biochemistry ; 40(13): 4087-95, 2001 Apr 03.
Article in English | MEDLINE | ID: mdl-11300789

ABSTRACT

We investigated the effects of the nonnucleoside reverse transcriptase inhibitor-resistant mutant Y181C on RNA 5'-end-directed RNase H cleavage by HIV-1 reverse transcriptase, using an RNA.DNA hybrid in which a radiolabeled RNA 5' end was recessed. Y181C produced a higher ratio of secondary (9 nucleotide long) to primary (18 nucleotide long) products than wild type. When the RNA was 3'-end-labeled, Y181C generated a long product, which results when secondary cleavage precedes the primary. When using an RNA.DNA hybrid in which the labeled RNA 5' end and DNA 3' end were flush, formation of secondary product by both enzymes was inhibited. Under these conditions, Y181C cleaved closer to the RNA 5' end than wild type. Studies with this substrate labeled at the RNA 3' end showed that Y181C is no more likely than wild type to cleave toward the RNA 3' end. Thus, Y181C RT has a strong preference to cleave in the direction of the RNA 5' end even when secondary cleavage is prevented, resulting in a disruption of the normal sequence of primary followed by secondary cleavages.


Subject(s)
Cysteine/genetics , HIV Reverse Transcriptase/antagonists & inhibitors , HIV Reverse Transcriptase/genetics , HIV-1/enzymology , Mutagenesis, Site-Directed , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H/metabolism , Tyrosine/genetics , 3' Untranslated Regions/genetics , 3' Untranslated Regions/metabolism , 5' Untranslated Regions/genetics , 5' Untranslated Regions/metabolism , DNA, Viral/genetics , DNA, Viral/metabolism , Drug Resistance, Microbial , HIV Reverse Transcriptase/metabolism , HIV-1/drug effects , HIV-1/genetics , Humans , Hydrolysis , RNA, Viral/genetics , RNA, Viral/metabolism
7.
J Virol ; 74(18): 8390-401, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10954539

ABSTRACT

Three mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (V106A, V179D, and Y181C), which occur in clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), were analyzed for RNA- and DNA-dependent DNA polymerization and RNase H cleavage. All mutants demonstrated processivities of polymerization that were indistinguishable from wild-type enzyme under conditions in which deoxynucleoside triphosphates were not limiting. The V106A reverse transcriptase demonstrated a three- to fourfold slowing of both DNA 3'-end-directed and RNA 5'-end-directed RNase H cleavage relative to both wild-type and V179D enzymes, similar to what was observed for P236L in a previously published study (P. Gerondelis et al., J. Virol. 73:5803-5813, 1999). In contrast, the Y181C reverse transcriptase demonstrated a selective acceleration of the secondary RNase H cleavage step during both modes of RNase H cleavage. The relative replication fitness of these mutants in H9 cells was assessed in parallel infections as well as in growth competition experiments. Of the NNRTI-resistant mutants, V179D was more fit than Y181C, and both of these mutants were more fit than V106A, which demonstrated the greatest reduction in RNase H cleavage. These findings, in combination with results from previous work, suggest that abnormalities in RNase H cleavage are a common characteristic of HIV-1 mutants resistant to NNRTIs and that combined reductions in the rates of DNA 3'-end- and RNA 5'-end-directed cleavages are associated with significant reductions in the replication fitness of HIV-1.


Subject(s)
HIV Reverse Transcriptase/genetics , HIV-1/genetics , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H/metabolism , Virus Replication , Cells, Cultured , Drug Resistance, Microbial , HIV Reverse Transcriptase/antagonists & inhibitors , HIV Reverse Transcriptase/metabolism , HIV-1/physiology , Humans , Mutagenesis, Site-Directed , Mutation
8.
J Infect Dis ; 182(1): 316-20, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10882615

ABSTRACT

Nonnucleoside reverse-transcriptase inhibitors (NNRTIs) can rapidly select for drug-resistant human immunodeficiency virus type 1 (HIV-1) variants, although their effect on HIV-1 quasi-species diversity is unknown. To determine if changes in env gene diversification occur with NNRTI therapy, we used the heteroduplex tracking assay (HTA) to study HIV-1 env sequence diversity in 2 groups of patients: those who were on no therapy or were on chronic antiretroviral therapy and those who had just initiated NNRTIs. Forty-nine paired samples from 46 patients were analyzed. Fourteen of 32 paired samples from the NNRTI group and 9 of 17 paired samples from the control group had HTA changes (P>.10). There was no correlation between HTA change and sampling time interval, baseline virus load, change in virus load, or development of NNRTI resistance. Thus, we found no significant correlation of NNRTI therapy with changes in env HTA patterns, suggesting that these treatments had little short-term impact on HIV-1 quasi-species diversity.


Subject(s)
Genes, Viral , HIV Envelope Protein gp120/genetics , HIV Infections/virology , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Drug Resistance, Microbial , Evolution, Molecular , HIV Infections/drug therapy , HIV Infections/genetics , HIV-1/genetics , Heteroduplex Analysis , Humans , Sequence Analysis
9.
JAMA ; 283(18): 2417-26, 2000 May 10.
Article in English | MEDLINE | ID: mdl-10815085

ABSTRACT

OBJECTIVE: Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing. PARTICIPANTS: An International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing. EVIDENCE AND CONSENSUS PROCESS: The full panel met regularly between January and October 1999. Resistance and resistance testing data appearing in the last decade through April 2000 and presentations at national and international research conferences were reviewed. Recommendations and considerations were developed by 100% group consensus, acknowledging that definitive data to support final recommendations are not yet available. CONCLUSIONS: Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings. Resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women. It should be considered in treatment-naive patients with established infection, but cannot be firmly recommended in this setting. Testing also should be considered prior to initiating therapy in patients with acute HIV infection, although therapy should not be delayed pending the results. Expert interpretation is recommended given the complexity of results and assay limitations.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , Microbial Sensitivity Tests , Adult , Anti-HIV Agents/therapeutic use , Clinical Trials as Topic , DNA, Viral/analysis , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Female , Genotype , HIV-1/genetics , Humans , Phenotype , Polymerase Chain Reaction , Pregnancy , Pregnancy Complications, Infectious/drug therapy , RNA, Viral/analysis , Treatment Failure
10.
Antiviral Res ; 45(1): 47-58, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10774589

ABSTRACT

RATIONALE: To determine the dosage requirements and pharmacokinetics of atevirdine, a non-nucleoside reverse transcriptase inhibitor and its N-dealkylated metabolite (N-ATV) during phase I studies in patients receiving atevirdine alone or in combination with zidovudine. DESIGN: Two open label, phase I studies conducted by the adult AIDS Clinical Trials Group (ACTG) in which atevirdine was administered every 8 h with weekly dosage adjustments to attain targeted trough plasma atevirdine concentrations. SETTING: Five Adult AIDS Clinical Trials Units. PATIENTS: Fifty patients (ACTG 199; n = 20 and ACTG 187; n = 30) with HIV-1 infection and < or =500 CD4+ lymphocytes/mm3. INTERVENTION: ACTG 199; 12 weeks of therapy with atevirdine (dose-adjusted to achieve plasma trough atevirdine concentrations of 5-10 microM) and zidovudine (200 mg every 8 h). ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM). MEASUREMENTS: ACTG 199: atevirdine, N-ATV and zidovudine trough determinations weekly (all patients) and intensive pharmacokinetics (selected patients) prior to and at 6 and 12 weeks during combination therapy. ACTG 187: atevirdine and N-ATV trough concentrations over a 12 week period. Intensive pharmacokinetic studies were conducted prior to and at 4 and/or 8 weeks during atevirdine monotherapy in female patients. RESULTS: Atevirdine plasma concentrations demonstrated considerable interpatient variability which was minimized by the adjustment of maintenance doses (range: 600-3900 mg/day) to achieve the desired trough concentrations. In ACTG 187, the mean number of weeks to attain the target value, and the percentage of patients who attained the target, was group I (5-11 microM): 2.7+/-2.4 weeks (92%); group II (12-21 microM): 2.6+/-1.8 (64%); and group III (22-31 microM): 7.0+/-5.6 weeks (27%). In ACTG 199 it was 3.2+/-5.2 weeks (95%) to achieve a 5-10 microM trough. Atevirdine demonstrated a mono- or bi-exponential decline among most of the patients studied after the first dose. During multiple-dosing a number of patterns of atevirdine disposition were observed including; rapid absorption with Cmax at 0.5-1 h, delayed absorption with Cmax at 3-4 h; minimal Cmax to Cmin fluctuation and Cmax to Cmin ratios of > 4. N-ATV (an inactive metabolite) patterns were characterized on day one by rapid appearance of the metabolite which peaked at 2-3 h after the dose and declined in a mono- or bi-exponential manner. At steady-state N-ATV patterns demonstrated minimal Cmax to Cmin fluctuations with some of the patients having more stable plasma N-ATV concentrations, while others had greater fluctuations week to week. CONCLUSIONS: Considerable interpatient variability was noted in the pharmacokinetics of atevirdine. The variation in drug disposition was reflected in the range of daily doses required to attain the targeted trough concentrations. Atevirdine metabolism did not appear to reach saturation during chronic dosing in many of our patients, as reflected by the pattern of N-ATV/ATV ratios in plasma and saturation was not an explanation for the variation in dosing requirements. No apparent differences were noted between males and females, and atevirdine did not appear to influence zidovudine disposition.


Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , HIV Infections/drug therapy , HIV-1 , Piperazines/administration & dosage , Piperazines/pharmacokinetics , Adult , Anti-HIV Agents/blood , Area Under Curve , Female , HIV Infections/metabolism , HIV-1/drug effects , Humans , Male , Middle Aged , Piperazines/blood , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/blood , Reverse Transcriptase Inhibitors/pharmacokinetics , Sex Characteristics , Zidovudine/administration & dosage , Zidovudine/pharmacokinetics
11.
Antimicrob Agents Chemother ; 44(3): 794-7, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10681363

ABSTRACT

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.


Subject(s)
Anti-HIV Agents/pharmacology , Delavirdine/pharmacology , HIV Infections/virology , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Mutation , Adult , Anti-HIV Agents/therapeutic use , Delavirdine/therapeutic use , Drug Resistance, Microbial/genetics , Female , HIV Infections/drug therapy , HIV-1/genetics , HIV-1/isolation & purification , Humans , Male , Middle Aged , Molecular Sequence Data , RNA, Viral/blood , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/therapeutic use
12.
J Virol ; 73(7): 5803-13, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10364332

ABSTRACT

The nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) delavirdine (DLV) selects in vitro for the human immunodeficiency virus type 1 (HIV-1) RT mutation P236L, which confers high-level resistance to DLV but not other NNRTIs. Unexpectedly, P236L has developed infrequently in HIV-1 isolates obtained from patients receiving DLV; K103N is the predominant resistance mutation observed in that setting. We characterized the replication fitness of viruses derived from pNL4-3 containing P236L or K103N in both H9 and primary human peripheral blood mononuclear cell cultures infected in parallel with the two mutants. In the absence of DLV, p24 production by wild-type virus occurred more rapidly and to higher levels than with either mutant; P236L consistently demonstrated a two- to threefold decrease in p24 relative to K103N. At low levels of DLV, growth of wild-type virus was severely inhibited, and K103N replicated two- to threefold more efficiently than P236L. At high concentrations of DLV, P236L replication and K103N replication were both inhibited. Recombinant RTs containing K103N or P236L were analyzed for DNA polymerization on heteropolymeric RNA templates and RNase H degradation of RNA-DNA hybrids. Neither mutant demonstrated defects in polymerization. K103N demonstrated normal RNA 5'-end-directed RNase H cleavage and slowed DNA 3'-end-directed RNase H cleavage compared to wild-type RT. P236L demonstrated slowing of both DNA 3'-end- and RNA 5'-end-directed RNase H cleavage, consistent with its reduced replication efficiency relative to K103N. These data suggest that NNRTI resistance mutations can lead to reductions in the efficiency of RNase H cleavage, which may contribute to a reduction in the replication fitness of HIV-1.


Subject(s)
Anti-HIV Agents/pharmacology , DNA, Viral/metabolism , Defective Viruses/physiology , Delavirdine/pharmacology , HIV-1/physiology , RNA, Viral/metabolism , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H/metabolism , Virus Replication/drug effects , 5' Untranslated Regions , Cell Line , Defective Viruses/drug effects , Drug Resistance, Microbial , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , HeLa Cells , Humans , Kinetics , Mutagenesis
13.
J Infect Dis ; 179(6): 1405-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10228061

ABSTRACT

Ninety-three women with human immunodeficiency virus type 1 (HIV-1) infection were enrolled in a cross-sectional study to evaluate the relationship between plasma HIV-1 RNA levels and coincident cervical infection and disease caused by human papillomaviruses (HPVs). HIV-1 RNA plasma levels of >10,000 copies/mL were highly associated with the presence in cervical specimens of HPV DNA of oncogenic (high risk) virus genotypes (P=.006; relative risk, 2.57). In addition, similar HIV-1 RNA plasma levels were associated with abnormal Pap smears (P=.01; relative risk, 2.11). In this study, 81% of women with high-risk HPV cervical infection had abnormal Pap smears. Measurement of HIV-1 RNA plasma levels may help to identify a subgroup of HIV-1-infected women at increased risk for cervical HPV infection and disease.


Subject(s)
HIV Infections/blood , HIV-1 , Papillomaviridae , Papillomavirus Infections/epidemiology , RNA, Viral/blood , Tumor Virus Infections/epidemiology , Adult , Aged , Cervix Uteri/pathology , Cervix Uteri/virology , Cross-Sectional Studies , Female , HIV Infections/complications , Humans , Middle Aged , New York/epidemiology , Outpatient Clinics, Hospital , Papanicolaou Test , Papillomavirus Infections/complications , Tumor Virus Infections/complications , Vaginal Smears
14.
Antimicrob Agents Chemother ; 43(6): 1373-8, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10348755

ABSTRACT

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 microM). A total of 113 subjects were analyzed. At week 2, the mean HIV type 1 (HIV-1) RNA level declines among the subjects in the three delavirdine arms were similar (0.87, 1.08, and 1.02 log10 for the low, middle, and high target arms, respectively), but by week 8, the subjects in the pooled delavirdine arms showed only a 0.10 log10 reduction. In the subjects in the nucleoside arm, mean HIV-1 RNA level reductions at weeks 2 and 8 were 0.67 and 0.55 log10, respectively. Because viral suppression by delavirdine was not maintained, the trial was stopped early. Rash, which was usually self-limited, developed in 36% of subjects who received delavirdine. Delavirdine monotherapy has potent anti-HIV activity at 2 weeks, but its activity is time limited due to the rapid emergence of drug resistance.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Delavirdine/therapeutic use , HIV-1 , Acquired Immunodeficiency Syndrome/virology , Adult , CD4 Lymphocyte Count , Delavirdine/adverse effects , Delavirdine/blood , Dose-Response Relationship, Drug , Female , HIV-1/genetics , Humans , Male , RNA, Viral/blood
15.
J Virol Methods ; 75(1): 93-104, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9820578

ABSTRACT

Thirteen laboratories evaluated the reproducibility of sequencing methods to detect drug resistance mutations in HIV-1 reverse transcriptase (RT). Blinded, cultured peripheral blood mononuclear cell pellets were distributed to each laboratory. Each laboratory used its preferred method for sequencing proviral DNA. Differences in protocols included: DNA purification; number of PCR amplifications; PCR product purification; sequence/location of PCR/sequencing primers; sequencing template; sequencing reaction label; sequencing polymerase; and use of manual versus automated methods to resolve sequencing reaction products. Five unknowns were evaluated. Thirteen laboratories submitted 39043 nucleotide assignments spanning codons 10-256 of HIV-1 RT. A consensus nucleotide assignment (defined as agreement among > or = 75% of laboratories) could be made in over 99% of nucleotide positions, and was more frequent in the three laboratory isolates. The overall rate of discrepant nucleotide assignments was 0.29%. A consensus nucleotide assignment could not be made at RT codon 41 in the clinical isolate tested. Clonal analysis revealed that this was due to the presence of a mixture of wild-type and mutant genotypes. These observations suggest that sequencing methodologies currently in use in ACTG laboratories to sequence HIV-1 RT yield highly concordant results for laboratory strains; however, more discrepancies among laboratories may occur when clinical isolates are tested.


Subject(s)
DNA, Viral/analysis , HIV Reverse Transcriptase/genetics , HIV-1/enzymology , Laboratories/standards , Mutation , Sequence Analysis, DNA/methods , Codon , Drug Resistance, Microbial , Gene Amplification , HIV-1/drug effects , HIV-1/genetics , Humans , Polymerase Chain Reaction , Proviruses/genetics , Reproducibility of Results , Sequence Analysis, DNA/standards , Zidovudine/pharmacology
16.
J Acquir Immune Defic Syndr Hum Retrovirol ; 19(2): 135-44, 1998 Oct 01.
Article in English | MEDLINE | ID: mdl-9768622

ABSTRACT

The safety, tolerability, and antiviral activity of atevirdine (ATV), a nonnucleoside reverse transcriptase inhibitor, were studied in a phase I/II clinical trial (ACTG 187) of patients with CD4 counts < or =500/mm3. In all, 34 HIV-1-infected patients were randomized to receive ATV for 12 weeks in doses chosen to achieve one of three serum trough levels: 5 to 13 microM, 14 to 22 microM, or 23 to 31 microM. Rash was the most common adverse event, with a grade 3 or 4 rash occurring in 4 patients. No significant change from baseline in HIV-1 plasma RNA mean copy number was detected at week 4 (+0.09 log10 copies/ml; p = .30). However, some evidence indicated moderate antiviral activity at week 4, based on median changes in CD4 count (+23/mm3; p = .05), and viral peripheral blood mononuclear cell (PBMC) titer (-0.68 log10) copies/ml; p = .03). In addition, 2 of 4 patients with detectable baseline serum p24 antigen showed declines of >50%. HIV-1 resistance to ATV was detected in 41% of patients and was most commonly associated with RT mutations K103N and Y181C. In contrast, the Y181C mutation was not detected in ATV-resistant isolates obtained from patients enrolled in ACTG 199, a study of ATV given in combination with zidovudine. Under the conditions of this study, ATV failed to demonstrate significant antiretroviral activity. However, transient in vivo activity might have been obscured by rapid development of resistance coupled with inadequate sampling at early time points following initiation of ATV therapy.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1 , Piperazines/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adult , Anti-HIV Agents/pharmacology , CD4 Lymphocyte Count , Cells, Cultured , Cohort Studies , Drug Eruptions , Drug Resistance, Microbial/genetics , Female , HIV Core Protein p24/blood , HIV Reverse Transcriptase/antagonists & inhibitors , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , HIV-1/genetics , HIV-1/immunology , Humans , Leukocytes, Mononuclear/virology , Male , Middle Aged , Piperazines/pharmacology , RNA, Viral/blood , Reverse Transcriptase Inhibitors/pharmacology , Viral Load
17.
JAMA ; 279(24): 1984-91, 1998 Jun 24.
Article in English | MEDLINE | ID: mdl-9643863

ABSTRACT

OBJECTIVES: To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice. PARTICIPANTS: The International AIDS Society-USA assembled a panel of 13 physicians with expertise in basic science, clinical research, and patient care relevant to HIV resistance to antiretroviral drugs. EVIDENCE: We reviewed available data from published reports and presented at national and international research conferences. Basic science research, clinical trial results, and expert opinions were used to form the basis of this report. Data on methods for and characteristics of specific genotypic and phenotypic assays were obtained from manufacturers and service providers. CONSENSUS PROCESS: The panel met regularly between October 1997 and April 1998. Panel subgroups developed and discussed different sections of the report before discussing them with the entire panel. Conclusions and suggested approaches to the use of resistance testing were determined by group consensus. CONCLUSIONS: Plasma HIV RNA level and CD4+ cell count are the primary values that should be used to guide the initiation of antiretroviral therapy and subsequent changes in therapy. Possible causes of treatment failure other than development of drug resistance that should be considered are adherence, drug potency, and pharmacokinetic issues. Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management. Assays under development need validation, standardization, and a clearer definition of their clinical roles. Possible current roles of resistance testing for choosing an initial regimen or changing antiretroviral therapy, as well as possible implications of the presence or absence of phenotypic resistance and genotypic changes, are discussed.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Genes, Viral , Genotype , HIV Protease Inhibitors/pharmacology , HIV-1/genetics , Humans , Mutation , Phenotype , Reverse Transcriptase Inhibitors/pharmacology , Viral Load
18.
N Engl J Med ; 337(11): 725-33, 1997 Sep 11.
Article in English | MEDLINE | ID: mdl-9287227

ABSTRACT

BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. RESULTS: The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. CONCLUSIONS: Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1 , Indinavir/therapeutic use , Acquired Immunodeficiency Syndrome/prevention & control , Adult , Anti-HIV Agents/adverse effects , CD4 Lymphocyte Count , Disease Progression , Double-Blind Method , Drug Therapy, Combination , Female , HIV Infections/immunology , HIV Infections/mortality , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/therapeutic use , Humans , Indinavir/adverse effects , Lamivudine/adverse effects , Lamivudine/therapeutic use , Male , RNA, Viral/blood , Reverse Transcriptase Inhibitors/therapeutic use , Stavudine/adverse effects , Stavudine/therapeutic use , Zidovudine/adverse effects , Zidovudine/therapeutic use
19.
J Acquir Immune Defic Syndr Hum Retrovirol ; 14(2): 136-44, 1997 Feb 01.
Article in English | MEDLINE | ID: mdl-9052722

ABSTRACT

Previous studies have shown that the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase mutation Y181C, which confers high-level resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), develops rarely during therapy with NNRTIs plus zidovudine. To determine whether didanosine (ddI) is also effective in preventing the emergence of Y181C, we analyzed delavirdine (DLV) susceptibilties and reverse transcriptase sequences of isolates obtained from patients enrolled in a pharmacokinetic study of DLV and ddI. Nine NNRTI-naive patients were evaluated. Seven received DLV/ddI and two received DLV/ddI/zidovudine. Median durations of prior zidovudine and ddI were 26 and 15 months, respectively. Isolates from eight of nine patients had a mutation(s) associated with nucleoside resistance at entry. After treatment with DLV and ddI alone, isolates from five of seven patients developed Y181C, four in combination with K103N. Thus, in this group of nucleoside-experienced patients, combination therapy with DLV/ddI did not prevent the emergence of Y181C.


Subject(s)
Anti-HIV Agents/therapeutic use , Didanosine/therapeutic use , HIV Infections/drug therapy , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Indoles/therapeutic use , Piperazines/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adult , Anti-HIV Agents/pharmacology , Delavirdine , Didanosine/pharmacology , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Female , HIV Infections/virology , HIV-1/classification , HIV-1/enzymology , HIV-1/genetics , Humans , Male , Mutation , Phenotype , RNA, Viral/blood , Reverse Transcriptase Inhibitors/pharmacology , Viral Load , Zidovudine/pharmacology , Zidovudine/therapeutic use
20.
Sex Transm Dis ; 23(4): 273-6, 1996.
Article in English | MEDLINE | ID: mdl-8836019

ABSTRACT

BACKGROUND AND OBJECTIVES: Among the various treatment modalities for condyloma acuminatum, excisional cold-blade surgery appears excellent but it has been little studied and little used, particularly for lesions not located in the perianal area. GOALS: To examine the efficacy and complications of scissors excision of single anogenital warts. STUDY DESIGN: Retrospective analysis of single warts completely excised with scissors for the purpose of biopsy before patient entry in a randomized, placebo-controlled study of the efficacy and safety of various parenteral interferons in combination with cryotherapy. RESULTS: Of 152 patients entered in the main study, 85 patients were available for analysis. At 4 and 16 weeks after excision, 16 of 85 (19%) and 14 of 68 (21%) of the excised lesions recurred. After at 6 least months of follow-up, 2 of 11 (18%) of the excision sites demonstrated some evidence of pigmentation changes. CONCLUSIONS: Scissors excision of single anogenital warts has a high rate of success and acceptable long-term side-effects.


Subject(s)
Biopsy , Condylomata Acuminata/pathology , Condylomata Acuminata/surgery , Adult , Antiviral Agents/therapeutic use , Biopsy/adverse effects , Biopsy/methods , Combined Modality Therapy , Condylomata Acuminata/etiology , Cryosurgery , Female , Humans , Interferons/therapeutic use , Male , Recurrence , Retrospective Studies , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...